Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
This Phase I study of sorafenib in high risk hepatocellular cancer patients after liver
transplantation will study 24 subjects for about 5 years. Each subject will receive sorafenib
for 6 months. Safety and effectiveness on the post transplant, high risk HCC patients will be
studied.